Diabetes Dementia Breakthrough: Enzyme Blocker Restores Brain Blood Flow and Memory in Rats

One of the most troubling intersections in modern medicine is the well-documented link between type 2 diabetes and Alzheimer’s disease-related dementias, a connection that has left scientists searching for therapies capable of protecting the diabetic brain. Now, a team of researchers reporting in GeroScience has demonstrated that blocking a single metabolic enzyme can rescue memory, restore cerebral blood flow, and preserve neurons in aged rats with diabetes-related dementia, offering one of the most comprehensive mechanistic case yet for a new class of disease-modifying drugs. The compound, an inhibitor of soluble epoxide hydrolase known as TPPU, did not cure the animals’ diabetes, yet it shielded their brains from the vascular and inflammatory cascade that normally erodes cognition, suggesting that the diabetic brain can be protected even when blood sugar remains elevated.

The enzyme at the center of the story, soluble epoxide hydrolase, or sEH, has been attracting growing attention from geneticists and vascular biologists alike. Genome-wide association studies have linked variants in the gene encoding sEH to Alzheimer’s disease and related dementias, and the enzyme is expressed widely throughout the central nervous system, in neurons, endothelial cells, vascular smooth muscle cells, astrocytes, and microglia. Its biochemical role is deceptively simple: it rapidly converts epoxy fatty acids, including the anti-inflammatory and vasodilatory epoxyeicosatrienoic acids produced by cytochrome P450 enzymes, into far less active dihydroxyeicosatrienoic acids. When sEH levels rise, the brain loses access to these protective lipid mediators precisely when it needs them most. The researchers found that sEH protein expression was significantly elevated in the brains of elderly diabetic rats, reaching roughly 1.6-fold the levels seen in age-matched controls, and that nine weeks of chronic TPPU treatment brought those levels back down to a range indistinguishable from healthy animals.

The behavioral consequences of this intervention were striking. In the novel object recognition test, which probes long-term non-spatial memory dependent on both cortical and hippocampal networks, untreated diabetic rats performed poorly, with a recognition index of just 0.34 compared with 0.61 in healthy controls, and a negative discrimination index indicating they actually preferred familiar objects over new ones. Chronic TPPU treatment lifted the recognition index to 0.53 and pushed the discrimination index back into positive territory, indicating a genuine restoration of memory rather than a marginal improvement. Notably, the drug did not rescue the animals’ locomotor deficits, as measured in the open field test, which the authors interpret as evidence that the cognitive gains reflect true neural protection rather than simply more movement or exploration. Intriguingly, treated animals did venture more frequently into the center of the open arena, a sign of reduced anxiety-like behavior that aligns with the drug’s anti-inflammatory effects on frontal cortical and amygdala circuitry.

To understand how an enzyme inhibitor could produce such broad cognitive benefits, the team turned to the cerebral vasculature, where the earliest damage in both Alzheimer’s disease and diabetes-related dementia is thought to occur. Using ex vivo pressure myography, they isolated middle cerebral arteries and penetrating arterioles from the rats and measured their ability to constrict in response to pressure, the myogenic response that underpins cerebral blood flow autoregulation. Diabetic vessels showed a characteristic pattern of dysfunction: elevated basal tone at low pressures but an inability to sustain constriction at high pressures, with autoregulatory breakthrough occurring around 120 mmHg instead of the normal 140 to 150 mmHg. TPPU treatment stabilized the myogenic response across the entire pressure spectrum, preventing the forced dilation that transmits dangerous pressure surges to the fragile microcirculation. Laser speckle contrast imaging in living animals confirmed the functional significance of these findings, showing that treated diabetic rats maintained stable cortical perfusion profiles even at elevated systemic pressures, while untreated animals displayed hot spots of hyperperfusion that signal vascular stress.

Perhaps the most dramatic vascular rescue involved neurovascular coupling, the elegant mechanism by which active neurons recruit local increases in blood flow. When the researchers mechanically deflected the rats’ whiskers at 10 hertz, control animals responded with a robust 31 percent increase in cortical blood flow within the somatosensory cortex. In untreated diabetic rats, this response was nearly abolished, reaching only about 6 percent. After chronic TPPU treatment, the hyperemic response rebounded to 30 percent, statistically indistinguishable from healthy controls. The team traced this rescue, at least in part, to the inward-rectifier potassium channel Kir2.1, which sits on capillary endothelial cells and conducts retrograde electrical signals from active brain tissue back to upstream arterioles. In isolated pressurized capillary-arteriole preparations, local application of potassium chloride to capillary terminals normally dilates the feeding arteriole by about 23 percent, but the response was halved in diabetic vessels. Immunohistochemistry revealed that TPPU significantly increased the coverage of Kir2.1 channels along the capillary basement membrane, providing a concrete molecular mechanism for the restored electrical signaling.

The protective effects extended deep into the architecture of the blood-brain barrier itself. Western blot analysis showed that the tight junction proteins zonula occludens-1 and occludin, which seal the gaps between endothelial cells and prevent leakage of blood-borne toxins into brain tissue, were reduced to roughly half of normal levels in the diabetic brain. Chronic TPPU treatment restored both proteins to near-control levels. Equally important, the drug counteracted capillary rarefaction, the wholesale loss of microvessels that starves brain tissue of oxygen and nutrients. Quantitative analysis of lectin-stained tissue revealed that capillary density in the hippocampal CA1, CA3, and dentate gyrus subfields, as well as in the cortex, had fallen by roughly half in untreated diabetic rats, and that TPPU treatment restored density to values matching or even exceeding those of healthy controls across all four regions.

Downstream of the vascular rescue, the researchers documented a profound calming of the brain’s inflammatory environment. The hippocampus of untreated diabetic rats was riddled with activated astrocytes and microglia, the resident immune cells whose chronic reactivity is a hallmark of neurodegenerative disease. Activated astrocyte counts in the CA1 region, for example, soared from about 4 per field in controls to nearly 31 in diabetic animals, and activated microglia climbed from fewer than 2 to more than 12. TPPU treatment cut both counts substantially, though not entirely to baseline, and correspondingly reduced hippocampal levels of the astrocytic marker GFAP and the microglial marker Iba1. Multiplex ELISA profiling added a revealing nuance: while classical proinflammatory cytokines such as TNF-alpha, IL-6, and IL-1beta remained unchanged, the chemokines MCP-1, RANTES, and MIP-1alpha, which recruit and activate glial cells, were significantly elevated in diabetic hippocampus and normalized by TPPU. The authors suggest this chemokine-selective effect reflects the ability of stabilized epoxy fatty acids to block nuclear factor-kappa B signaling in endothelial cells, silencing the focal chemoattractant signals that drive glial recruitment without altering systemic immune status.

The cellular payoff of all this vascular and inflammatory protection was visible in the neurons themselves. Untreated diabetic rats lost significant numbers of neurons in the hippocampal CA1 and CA3 subfields, regions critically vulnerable to metabolic and hypoxic injury, and showed marked downregulation of the postsynaptic scaffold protein PSD95 and the presynaptic marker synaptophysin, twin indicators of eroding synaptic integrity. Chronic TPPU treatment preserved neuronal survival in both subfields and restored expression of both synaptic proteins to near-control levels. The authors argue that this cascade, from stabilized autoregulation to preserved tight junctions to reduced gliosis to intact synapses, represents a coherent mechanistic chain linking vascular health to cognitive function, and that intervening at the vascular level may be the most effective way to protect the diabetic brain before irreversible neurodegeneration takes hold.

Important caveats remain before this science can translate to the clinic. The study was conducted exclusively in male rats, even though Alzheimer’s disease and diabetes-related dementia disproportionately affect women, and sex differences in sEH expression and oxylipin metabolism are well documented. The authors also note that neurovascular coupling depends on multiple mediators beyond Kir2.1, including nitric oxide, prostaglandins, and epoxyeicosatrienoic acids themselves, so the full mechanism of TPPU’s benefit likely involves several converging pathways. Questions about long-term safety, oxylipin profiles, and whether the drug enhances glymphatic clearance of amyloid and tau in the diabetic brain remain open. Still, with more than 830 million adults worldwide living with diabetes and no approved therapy to slow the cognitive decline it accelerates, the demonstration that a brain-penetrant sEH inhibitor can preserve memory, perfusion, and neurons despite persistent hyperglycemia marks a compelling proof of concept. Human clinical trials of sEH inhibitors are already underway for other indications, and this work provides a strong rationale for extending them to the growing population at risk of diabetes-related dementia.

Subject of Research: Soluble epoxide hydrolase inhibition as a therapy for cerebrovascular dysfunction and cognitive decline in diabetes-related dementia

Article Title: Inhibition of soluble epoxide hydrolase rescues cognitive deficits by preserving neurovascular integrity and attenuating glial and neuropathology in diabetic-related dementia

Article References: Fang, X., Border, J. J., Zhang, H., Morgan, G. C., Gregory, A., Hanscom-Trofy, Y., Dong, R., Yang, J., Hwang, S. H., Morisseau, C., Hammock, B. D., Fan, F., & Roman, R. J. (2026). Inhibition of soluble epoxide hydrolase rescues cognitive deficits by preserving neurovascular integrity and attenuating glial and neuropathology in diabetic-related dementia. GeroScience. https://doi.org/10.1007/s11357-026-02591-3

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02591-3

Keywords: soluble epoxide hydrolase, TPPU, diabetes-related dementia, neurovascular coupling, blood-brain barrier, Kir2.1, capillary rarefaction, neuroinflammation, hippocampus, cerebral blood flow, Alzheimer's disease, GeroScience